↑ 疾患リストへ ← 戻る

 1. 球脊髄性筋萎縮症 [臨床試験数:11,薬物数:14(DrugBank:8),標的遺伝子数:7,標的パスウェイ数:9] 

Searched query = "Spinal and bulbar muscular atrophy", "Spinobulbar muscular atrophy", "Kennedy disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03555578November 2, 201720 August 2018Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)Spinal and Bulbar Muscular AtrophyDrug: Leuprorelin AcetateTakedaRecruitingN/AN/AAll300Phase 1Japan
2JPRN-UMIN0000261502017/04/252 April 2019Safety and efficacy of mexiletine hydrochroride in spinal and bulbar muscular atrophy (SBMA) :a multicenter, randomised, double-blind, placebo-controlled trialSpinal and Bulbar Muscular AtrophyMexiletine Hydrochloride 300mg daily, for 4 weeks
placebo for 4 weeks
Nagoya University Graduate School of MedicineNot Recruiting20years-old80years-oldMale20Phase 2Japan
3JPRN-UMIN0000125032014/06/012 April 2019Effect of creatine in SBMA patients: A double-blind, placebo-controlled clinical studySpinal and Bulbar Muscular AtrophyCreatine monohydrate 10 g, daily for 8 weeks
Creatine monohydrate 15 g, daily for 8 weeks
placebo for 8 weeks
Department of Neurology, Nagoya University Graduate School of MedicineNot Recruiting20years-old80years-oldMale45Not applicableJapan
4NCT02024932February 4, 201415 April 2019Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular AtrophyA Two-part Placebo-controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy (SBMA)Spinal and Bulbar Muscular AtrophyDrug: BVS857;Drug: PlaceboNovartis PharmaceuticalsNot recruiting18 YearsN/AMale37Phase 2United States;Denmark;Germany;Italy
5JPRN-JMA-IIA0008002/201222 July 2019Phase 2 Clinical Trial of Leuprorelin acetate in patients with SBMA (JASMITT-2)Double-blind Placebo-controlled Phase 2 Clinical Trial of TAP-144-SR (3M) in patients with Spinal and Bulbar Muscular Atrophy (SBMA)Spinal and Bulbar muscular atrophyIntervention type:DRUG. Intervention1:TAP-144-SR(3M) , Dose form:INJECTION, Route of administration:SUBCUTANEOUS. Control intervention1:placebo, Dose form:INJECTION, Route of administration:SUBCUTANEOUS.JASMITT Clinical Trial OfficeJichi med college, Chiba univ., Univ of Tokyo, Tokyo med & dental univ.Not Recruiting>=30 YEARS<70 YEARSMale100Phase 2Japan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2010-022558-18-IT11/10/20102 October 2012A pilot trial with clenbuterol in spinal and bulbar muscular atrophy (SBMA).A pilot trial with clenbuterol in spinal and bulbar muscular atrophy (SBMA).spinal and bulbar muscular atrophy (SBMA)
MedDRA version: 15.0 Level: HLGT Classification code 10029317 Term: Neuromuscular disorders System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 15.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 15.0 Level: LLT Classification code 10047868 Term: Weakness of limbs System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
MedDRA version: 15.0 Level: PT Classification code 10013969 Term: Dyspnoea at rest System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: MONORES*30CPR 20MCG
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Clenbuterol
Concentration unit: µg microgram(s)
Concentration number: 20-
AZIENDA OSPEDALIERA DI PADOVAAuthorisedFemale: no
Male: yes
Italy
7NCT00851461April 20081 June 2015Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular AtrophyEffect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy in Thai PatientsSpinobulbar Muscular Atrophy;Kennedy's DiseaseDrug: Goserelin;Procedure: Electrophysiologic study;Procedure: tissue biopsyRamathibodi HospitalAstraZenecaNot recruiting20 YearsN/AMale10Phase 4Thailand
8JPRN-JMA-IIA0000913/09/20062 April 2019Phase III Clinical Trial of Leuprorelin acetate in Patients with SBMA (JASMITT)Double-blind Placebo-controlled Phase III Clinical Trial of TAP-144-SR (3M) in Patients with Spinal and Bulbar Muscular Atrophy (SBMA)Spinal and Bulbar Muscular Atrophy (SBMA)Intervention type:DRUG. Intervention1:TAP-144-SR(3M), Dose form:INJECTION, Route of administration:SUBCUTANEOUS. Control intervention1:placebo, Dose form:INJECTION, Route of administration:SUBCUTANEOUS.JASMITT Clinical Trial OfficeHokkaido University, Tohoku University, Jichi Medical College, Chiba University, University of Tokyo, Tokyo Medical and Dental University, NHO Sagamitara hospital, Niigata University, Hamamatsu Medical college, Kobe University, Tottori University, Nagasaki University, Kumamoto UniversityNot Recruiting>=30 YEARS<70 YEARSMale170Phase 3Japan
9NCT00303446March 200619 October 2017Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)Phase II Clinical Trial to Examine the Efficacy and Safety of Dutasteride in Patients With Kennedy's Disease (Spinal and Bulbar Muscular Atrophy)Kennedy's Disease;Spinal and Bulbar Muscular AtrophyDrug: Dutasteride;Drug: PlaceboNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting18 YearsN/AMale57Phase 2United States
10JPRN-UMIN0000004742003/09/012 April 2019Double-blind Placebo-controlled Clinical Trial of Leuprorelin acetate in Patients with Spinal and Bulbar Muscular Atrophy (SBMA)Spinal and bulbar muscular atrophy (SBMA)Leuprorelin acetate 3.75 mg subcutaneous injection every 4 weeks
Placebo subcutaneous injection every 4 weeks
Department of Neurology, Nagoya University School of MedicineNot Recruiting30years-old70years-oldMale40Phase 2Japan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00004771October 199219 February 2015Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron DiseaseSpinal Muscular Atrophy;Amyotrophic Lateral Sclerosis;Spinobulbar Muscular AtrophyDrug: leuprolide;Drug: testosteroneNational Center for Research Resources (NCRR)Ohio State UniversityNot recruiting18 YearsN/AMale40Phase 2

先頭へ